### Cardiovascular-Kidney-Metabolic Syndrome (CKM) A newly named condition, cardiovascular-kidney-metabolic syndrome (CKM), has been introduced to describe individuals affected by obesity, diabetes, heart disease, and kidney disease simultaneously. This term was announced by the American Heart Association on October 10, 2023, and aims to highlight the high risk of mortality from heart disease associated with these combined conditions. The recommendation was detailed in the journal Circulation. According to statistics, one-third of all U.S. adults have at least three risk factors for heart disease, metabolic disorders like diabetes, or kidney disease. The diagnosis of CKM is based on combined risk factors such as issues with weight, blood pressure, cholesterol, blood sugar, and kidney function. CKM syndrome is categorized into four stages, with the goal of providing a framework for individuals to work towards “CKM syndrome regression,” meaning moving to a lower stage. This can involve improving glucose control, cholesterol and blood pressure levels, weight, kidney function, and heart health. Dr. Chiadi E. Ndumele, the lead author of the advisory and an associate professor of medicine at Johns Hopkins University, emphasized the importance of addressing the connections among these conditions. Early screening for kidney and metabolic diseases can help initiate protective therapies sooner, effectively preventing heart disease and managing existing conditions.